Nova Therapeutics is developing small molecule antagonists of GPCRs for endocrine disorders and cancer. The lead compounds were developed based on molecular modeling of the receptors. These molecules have been shown to be specific with micromolar efficacy in cell models as well as patient derived cells. Nova will refine the existing molecular structures in order to increase efficacy and specificity. Absorption, distribution, metabolism and excretion (ADME) studies and pharmacokinetic studies will be done to select the compounds with the best pharmaceutical properties. Nova will also have a license to develop an orally available small molecule as an agonist of a GPCR receptor for treatment of brain and liver cancer.

For more information contact: Malini Vashistha, Ph.D.